Chapter 16 : Disease

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Disease, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815592/9781555814441_Chap16-1.gif /docserver/preview/fulltext/10.1128/9781555815592/9781555814441_Chap16-2.gif


This chapter reviews the salient features of infection caused by . inhabits the lumen of the colon and is not invasive. Nearly all strains produce toxins A and B, although some strains that produce only toxin B have been shown to cause disease. The genes and , which encode toxins A and B, respectively, are downregulated by the gene . colitis was originally recognized exclusively as a nosocomial infection and, subsequently, as a problem in extended care facilities. Strains of have been identified by restriction enzyme analysis (REA), pulsed-field gel electrophoresis (PFGE), restriction fragment length polymorphism analysis of the pathogenicity locus that includes genes for toxin production (toxinotyping), and PCR for , which encodes a binary toxin. Using these techniques, many distinct strains have been identified in patients with disease (CDD). In the epidemiologic setting of hospitalization with prior antimicrobial and/or chemotherapy, the clinical syndrome of CDD is usually easy to recognize. Abdominal discomfort and diarrhea, generally > 3 loose or watery bowel movements per day, develop over a period of a few days. Oral vancomycin was used to treat ‘‘staphylococcal enterocolitis’’ and clindamycin-associated diarrhea before the discovery that was responsible. Rifaximin is only minimally absorbed in the gastrointestinal tract after oral administration. Use of hypochlorite solution as a disinfectant and disposable rectal thermometers are also effective.

Citation: Musher D, Aslam S. 2008. Disease, p 313-335. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch16
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1.
Figure 1.

Dendrogram showing 22 isolates from the Michael E. DeBakey Veterans Affairs Medical Center during the prolonged outbreak of severe CDAD. Four of 22 isolates were NAP 1. The isolates were selected randomly and submitted to the Centers for Disease Control and Prevention for study. The photo was graciously provided by C. Kilgore and A. Thompson of the Centers for Disease Control and Prevention.

Citation: Musher D, Aslam S. 2008. Disease, p 313-335. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Aas, J.,, C. E. Gessert,, and J. S. Bakken. 2003. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36: 580585.
2. Aboudola, S.,, K. L. Kotloff,, L. Kyne,, M. Warny,, E. C. Kelly,, S. Sougioultzis,, P. J. Giannasca,, T. P. Monath,, and C. P. Kelly. 2003. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71: 16081610.
3. Ackermann, G.,, B. Loffler,, D. Adler,, and A. C. Rodloff. 2004. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob. Agents Chemother. 48: 22802282.
4. Aronsson, B.,, R. Mollby,, and C. E. Nord. 1985. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980–1982. J. Infect. Dis. 151: 476481.
5. Babakhani, F.,, J. Seddon,, N. Robert,, A. Gomez,, and P. Sears. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr. E-2076.
6. Babcock, G. J.,, T. J. Broering,, H. J. Hernandez,, R. B. Mandell,, K. Donahue,, N. Boatright,, A. M. Stack,, I. Lowy,, R. Graziano,, D. Molrine,, D. M. Ambrosino,, and W. D. Thomas, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74: 63396347.
7. Barbut, F.,, D. Decre,, B. Burghoffer,, D. Lesage,, F. Delisle,, V. Lalande,, M. Delmee,, V. Avesani,, N. Sano,, C. Coudert,, and J. C. Petit. 1999. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43: 26072611.
8. Barbut, F.,, A. Richard,, K. Hamadi,, V. Chomette,, B. Burghoffer,, and J. C. Petit. 2000. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38: 23862388.
9. Bartlett, J. G. 2002. Antibiotic-associated diarrhea. N. Engl. J. Med. 346: 334339.
10. Bartlett, J. G. 1990. Clostridium difficile: clinical considerations. Rev. Infect. Dis. 12 (Suppl. 2) : S243S251.
11. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145: 75864.
12. Bartlett, J. G. 1984. Treatment of antibiotic-associated pseudomembranous colitis. Rev. Infect. Dis. 6 (Suppl. 1) : S235S241.
13. Bartlett, J. G.,, T. W. Chang,, M. Gurwith,, S. L. Gorbach,, and A. B. Onderdonk. 1978. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 298: 531534.
14. Bartlett, J. G.,, T. W. Chang,, and A. B. Onderdonk. 1978. Comparison of five regimens for treatment of experimental clindamycin-associated colitis. J. Infect. Dis. 138: 8186.
15. Bartlett, J. G.,, A. B. Onderdonk,, R. L. Cisneros,, and D. L. Kasper. 1977. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J. Infect. Dis. 136: 701705.
16. Bartlett, J. G.,, F. J. Tedesco,, S. Shull,, B. Lowe,, and T. Chang. 1980. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 78: 431434.
17. Beales, I. L. 2002. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 51: 456.
18. Blossom, D. B.,, and L. C. McDonald. 2007. The challenges posed by reemerging Clostridium difficile infection. Clin. Infect. Dis. 45: 222227.
19. Boero M.,, E. Berti,, A. Morgando,, and G. Verma. 1990. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs vancomycin. Microbiol. Med. 5: 7477.
20. Bolton, R. P.,, and M. A. Culshaw. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27: 11691172.
21. Broekhuysen, J.,, A. Stockis,, R. L. Lins,, J. De Graeve,, and J. F. Rossignol. 2000. Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38: 387394.
22. Brooks, S. E.,, R. O. Veal,, M. Kramer,, L. Dore,, N. Schupf,, and M. Adachi. 1992. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect. Control Hosp. Epidemiol. 13: 98103.
23. Buggy, B. P.,, R. Fekety,, and J. Silva, Jr. 1987. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J. Clin. Gastroenterol. 9: 155159.
24. Cadle, R. M.,, M. D. Mansouri,, N. Logan,, D. R. Kudva,, and D. M. Kusher. 2007. Association of proton-pump inhibitors with treatment outcomes in Clostridium difficile colitis. Am. J. Health-System Pharm. 64: 23592363.
25. Cavagnaro, C.,, S. Berezin,, and M. S. Medow. 2003. Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis. Arch. Dis. Child. 88: 342344.
26. Centers for Disease Control and Prevention. 2005. Severe Clostridium difficile-associated disease in populations previously at low risk—four states. Morb. Mortal. Wkly. Rep. 54: 12011205.
27. Chang, T. W.,, S. L. Gorbach,, J. G. Bartlett,, and R. Saginur. 1980. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin. Gastroenterology 78: 15841586.
28. Cheng, S. H.,, F. Y. Chu,, S. H. Lo,, and J. J. Lu. 1999. Antimicrobial susceptibility of Clostridium difficile by E test. J. Microbiol. Immunol. Infect. 32: 116120.
29. Cherry, R. D.,, D. Portnoy,, M. Jabbari,, D. S. Daly,, D. G. Kinnear,, and C. A. Goresky. 1982. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 82: 849851.
30. Climo, M. W.,, D. S. Israel,, E. S. Wong,, D. Williams,, P. Coudron,, and S. M. Markowitz. 1998. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann. Intern. Med. 128: 989995.
31. de Lalla, F.,, R. Nicolin,, E. Rinaldi,, P. Scarpellini,, R. Rigoli,, V. Manfrin,, and A. Tramarin. 1992. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother. 36: 21922196.
32. de Lalla, F.,, G. Privitera,, E. Rinaldi,, G. Ortisi,, D. Santoro,, and G. Rizzardini. 1989. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob. Agents Chemother. 33: 11251127.
33. Delaney, J. A. C.,, S. Dial,, A. Barkun,, and S. Suissa. 2007. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg. Infect. Dis. 13: 761763.
34. Dendukuri, N.,, V. Costa,, M. McGregor,, and J. M. Brophy. 2005. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173: 167170.
35. Dial, S.,, K. Alrasadi,, C. Manoukian,, A. Huang,, and D. Menzies. 2004. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and casecontrol studies. CMAJ 171: 3338.
36. Dial, S.,, J. A. Delaney,, A. N. Barkun,, and S. Suissa. 2005. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 29892995.
37. Dial, S.,, J. A. Delaney,, V. Schneider,, and S. Suissa. 2006. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175: 745748.
38. Dubreuil, L.,, I. Houcke,, Y. Mouton,, and J. F. Rossignol. 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40: 22662270.
39. Dudley, M. N.,, J. C. McLaughlin,, G. Carrington,, J. Frick,, C. H. Nightingale,, and R. Quintiliani. 1986. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch. Intern. Med. 146: 11011104.
40. DuPont, H. L.,, Z. D. Jiang,, P. C. Okhuysen,, C. D. Ericsson,, F. J. de la Cabada,, S. Ke,, M. W. DuPont,, and F. Martinez-Sandoval. 2005. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann. Intern. Med. 142: 805812.
41. Durai, R. 2007. Epidemiology, pathogenesis, and management of Clostridium difficile infection. Dig. Dis. Sci. 52: 29582962.
42. Dzink, J.,, and J. G. Bartlett. 1980. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob. Agents Chemother. 17: 695698.
43. Ellames, D.,, M. Wilcox,, W. Fawley,, J. Freeman,, and C. Smith. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr. K-604.
44. Ertugrul, N.,, M. C. Rodriguez-Barradas,, D. M. Musher,, M. A. Ryan,, C. S. Agin,, S. J. Murphy,, M. Shayegani,, and D. A. Watson. 1997. BOX-polymerase chain reaction-based DNA analysis of nonserotypeable Streptococcus pneumoniae implicated in outbreaks of conjunctivitis. J. Infect. Dis. 176: 14011405.
45. Federal Register. 1994. Preventing the spread of vancomycin resistance—Report from the Hospital Infection Control Practices Advisory Committee. Fed. Regist. 59: 2575825763.
46. Fekety, R. 1997. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 92: 739750.
47. Fekety, R.,, L. V. McFarland,, C. M. Surawicz,, R. N. Greenberg,, G. W. Elmer,, and M. E. Mulligan. 1997. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 24: 324333.
48. Fekety, R.,, J. Silva,, B. Buggy,, and H. G. Deery. 1984. Treatment of antibiotic-associated colitis with vancomycin. J. Antimicrob. Chemother. 14 (Suppl. D) : 97102.
49. Fekety, R.,, J. Silva,, C. Kauffman,, B. Buggy,, and H. G. Deery. 1989. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am. J. Med. 86: 1519.
50. Fernandez, A.,, G. Anand,, and F. Friedenberg. 2004. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J. Clin. Gastroenterol. 38: 414418.
51. Finegold, S. M.,, D. Molitoris,, M. L. Vaisanen,, Y. Song,, C. Liu,, and M. Bolanos. 2004. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48: 48984902.
52. Flegel, W. A.,, F. Muller,, W. Daubener,, H. G. Fischer,, U. Hadding,, and H. Northoff. 1991. Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect. Immun. 59: 36593666.
53. Friedell, G. H.,, and E. Paige. 1954. Pseudomembranous enterocolitis following antibiotic therapy for pneumonia: report of a case. Am. J. Clin. Pathol. 24: 11591164.
54. Friedenberg, F.,, A. Fernandez,, V. Kaul,, P. Niami,, and G. M. Levine. 2001. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis. Colon Rectum 44: 11761180.
55. Gaynes, R.,, D. Rimland,, E. Killum,, H. K. Lowery,, T. M. Johnson II,, G. Killgore,, and F. C. Tenover. 2004. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis. 38: 640645.
56. Gerding, D. N. 1997. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin. Infect. Dis. 25 (Suppl. 2) : S206S210.
57. Gerding, D. N. 2005. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin. Infect. Dis. 40: 15981600.
58. Goorhuis, A.,, D. W. Notermans,, C. Harmanus,, D. Bakker,, T. van der Koof,, J. Corver,, and E. J. Kuijper. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. K-606.
59. Guzman, R.,, J. Kirkpatrick,, K. Forward,, and F. Lim. 1988. Failure of parenteral metronidazole in the treatment of pseudomembranous colitis. J. Infect. Dis. 158: 11461147.
60. Hecht, D. W.,, M. A. Galang,, S. P. Sambol,, J. R. Osmolski,, S. Johnson,, and D. N. Gerding. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51: 27162719.
61. Hickson, M.,, A. L. D’Souza,, N. Muthu,, T. R. Rogers,, S. Want,, C. Rajkumar,, and C. J. Bulpitt. 2007. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335: 80.
62. Jamal, W. Y.,, E. M. Mokaddas,, T. L. Verghese,, and V. O. Rotimi. 2002. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int. J. Antimicrob. Agents 20: 270274.
63. Johnson, S.,, A. Adelmann,, C. R. Clabots,, L. R. Peterson,, and D. N. Gerding. 1989. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 159: 340343.
64. Johnson, S.,, C. R. Clabots,, F. V. Linn,, M. M. Olson,, L. R. Peterson,, and D. N. Gerding. 1990. Nosocomial Clostridium difficile colonisation and disease. Lancet 336: 97100.
65. Johnson, S.,, C. Schriever,, M. Galang,, C. P. Kelly,, and D. N. Gerding. 2007. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44: 846848.
66. Juang, P.,, S. J. Skledar,, N. K. Zgheib,, D. L. Paterson,, E. N. Vergis,, W. D. Shannon,, N. T. Ansani,, and R. A. Branch. 2007. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am. J. Infect. Control 35: 131137.
67. Just, I.,, J. Selzer,, M. Wilm,, C. von Eichel-Streiber,, M. Mann,, and K. Aktories. 1995. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375: 500503.
68. Just, I.,, M. Wilm,, J. Selzer,, G. Rex,, C. von Eichel-Streiber,, M. Mann,, and K. Aktories. 1995. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J. Biol. Chem. 270: 1393213936.
69. Kaatz, G. W.,, S. D. Gitlin,, D. R. Schaberg,, K. H. Wilson,, C. A. Kauffman,, S. M. Seo,, and R. Fekety. 1988. Acquisition of Clostridium difficile from the hospital environment. Am. J. Epidemiol. 127: 12891294.
70. Keidan, S. E.,, and I. F. Sutherland. 1954. Staphylococcal pseudomembranous enterocolitis. Lancet 267: 11251126.
71. Kelly, C. P.,, C. Pothoulakis,, F. Vavva,, I. Castagliuolo,, E. F. Bostwick,, J. C. O’Keane,, S. Keates,, and J. T. LaMont. 1996. Anti- Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob. Agents Chemother. 40: 373379.
72. Khan, M. Y.,, and W. H. Hall. 1966. Staphylococcal enterocolitis—treatment with oral vancomycin. Ann. Intern. Med. 65: 18.
73. Khan, R.,, and J. Cheesbrough. 2003. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J. Hosp. Infect. 54: 104108.
74. Kyne, L.,, S. Sougioultzis,, L. V. McFarland,, and C. P. Kelly. 2002. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol. 23: 653659.
75. Kyne, L.,, M. Warny,, A. Qamar,, and C. P. Kelly. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357: 189193.
76. Kyne, L.,, M. Warny,, A. Qamar,, and C. P. Kelly. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342: 390397.
77. Laffan, A. M.,, M. F. Bellantoni,, W. B. Greenough III,, and J. M. Zenilman. 2006. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J. Am. Geriatr. Soc. 54: 10681073.
78. Lahikainen, E. 1953. Clinico-bacteriologic studies on acute otitis media. Acta Oto-Laryngol. 107 (Suppl.) : 182.
79. Layton, B. A.,, L. C. McDonald,, D. N. Gerding,, L. A. Liedtke,, and L. J. Strausbaugh. 2004. 42nd Annu. Meet. Infect. Dis. Soc. Am., Boston, 30 September to 3 October, 2004, abstr. 563, p. 150.
80. Limaye, A. P.,, D. K. Turgeon,, B. T. Cookson,, and T. R. Fritsche. 2000. Pseudomembranous colitis caused by a toxin A B + strain of Clostridium difficile. J. Clin. Microbiol. 38: 16961697.
81. Loft, S.,, M. Dossing,, H. E. Poulsen,, J. Sonne,, K. L. Olesen,, K. Simonsen,, and P. B. Andreasen. 1986. Influence of dose and route of administration on disposition of metronidazole and its major metabolites. Eur. J. Clin. Pharmacol. 30: 467473.
82. Loo, V. G.,, L. Poirier,, M. A. Miller,, M. Oughton,, M. D. Libman,, S. Michaud,, A. M. Bourgault,, T. Nguyen,, C. Frenette,, M. Kelly,, A. Vibien,, P. Brassard,, S. Fenn,, K. Dewar,, T. J. Hudson,, R. Horn,, P. Rene,, Y. Monczak,, and A. Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353: 24422449.
83. Louie, T. J.,, M. Gerson,, D. Grimard,, and D. Davidson. 2007. Results of a phase III trial comparing tolevamer, vancomycin, and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 14 to 18 September 2007, abstr. 3826.
84. Louie, T. J.,, J. Peppe,, C. K. Watt,, D. Johnson,, R. Mohammed,, G. Dow,, K. Weiss,, S. Simon,, J. F. John, Jr.,, G. Garber,, S. Chasan-Taber,, and D. M. Davidson. 2006. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43: 411420.
85. Lundsgaard-Hansen, P.,, A. Senn,, B. Roos,, and U. Waller. 1960. Staphylococcic enterocolitis. Report of six cases with two fatalities after intravenous administration of N-(pyrrolidinomethyl) tetracycline. JAMA 173: 10081013.
86. Lyerly, D. M.,, E. F. Bostwick,, S. B. Binion,, and T. D. Wilkins. 1991. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 59: 22152218.
87. Marchese, A.,, A. Salerno,, A. Pesce,, E. A. Debbia,, and G. C. Schito. 2000. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 46: 253266.
88. Mattila, K. J.,, V. V. Valtonen,, M. S. Nieminen,, and S. Asikainen. 1998. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin. Infect. Dis. 26: 719734.
89. Mayfield, J. L.,, T. Leet,, J. Miller,, and L. M. Mundy. 2000. Environmental control to reduce transmission of Clostridium difficile. Clin. Infect. Dis. 31: 9951000.
90. McDonald, L. C.,, G. E. Killgore,, A. Thompson,, R. C. Owens, Jr.,, S. V. Kazakova,, S. P. Sambol,, S. Johnson,, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353: 24332441.
91. McDonald, L. C.,, M. Owings,, and D. B. Jernigan. 2006. Increasing rates of Clostridium difficile infection among patients discharged from U.S. short stay hospitals, 1996–2003. Emerg. Infect. Dis. 12: 409415.
92. McFarland, L. V. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101: 812822.
93. McFarland, L. V.,, M. E. Mulligan,, R. Y. Kwok,, and W. E. Stamm. 1989. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320: 204210.
94. McFarland, L. V.,, C. M. Surawicz,, R. N. Greenberg,, R. Fekety,, G. W. Elmer,, K. A. Moyer,, S. A. Melcher,, K. E. Bowen,, J. L. Cox,, Z. Noorani, et al. 1994. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 19131918.
95. McNulty, C.,, M. Logan,, I. P. Donald,, D. Ennis,, D. Taylor,, R. N. Baldwin,, M. Bannerjee,, and K. A. Cartwright. 1997. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J. Antimicrob. Chemother. 40: 707711.
96. McVay, C. S.,, and R. D. Rolfe. 2000. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44: 22542258.
97. Miller, M. A. 2007. Clinical management of Clostridium difficile-associated disease. Clin. Infect. Dis. 45 (Suppl. 2) : S122S128.
98. Modena, S.,, S. Gollamudi,, and F. Friedenberg. 2006. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 40: 4954.
99. Mogg, G. A.,, Y. Arabi,, D. Youngs,, M. Johnson,, S. Bentley,, D. W. Burdon,, and M. R. Keighley. 1980. Therapeutic trials of antibiotic associated colitis. Scand. J. Infect. Dis. Suppl. 1980: 4145.
100. Mogg, G. A.,, R. H. George,, D. Youngs,, M. Johnson,, H. Thompson,, D. W. Burdon,, and M. R. Keighley. 1982. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br. J. Surg. 69: 137139.
101. Moshkowitz, M.,, E. Ben Baruch,, Z. Kline,, G. Moshe,, Z. Shimoni,, and F. Konikoff. 2004. Clinical manifestations and outcome of pseudomembranous colitis in an elderly population in Israel. Isr. Med. Assoc. J. 6: 201204.
102. Mulligan, M. E.,, S. D. Miller,, L. V. McFarland,, H. C. Fung,, and R. Y. Kwok. 1993. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin. Infect. Dis. 16 (Suppl. 4) : S239S244.
103. Musher, D. M.,, S. Aslam,, N. Logan,, S. Nallacheru,, I. Bhaila,, F. Borchert,, and R. J. Hamill. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40: 15861590.
104. Musher, D. M.,, F. Nuila,, and N. Logan. 2007. The long-term outcome of treatment of Clostridium difficile colitis. Clin. Infect. Dis. 45: 523524.
105. Musher, D. M.,, N. Logan,, R. J. Hamill,, H. L. DuPont,, A. Lentnek,, A. Gupta,, and J. F. Rossignol. 2006. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43: 421427.
106. Musher, D. M.,, N. Logan,, V. Mehendiratta,, N. A. Melgarejo,, S. Garud,, and R. J. Hamill. 2007. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob. Chemother. 59: 705710.
107. Musher, D. M.,, A. Manhas,, P. Jain,, F. Nuila,, A. Waqar,, N. Logan,, B. Marino,, and E. A. Graviss. 2007. Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. J. Clin. Microbiol. 45: 27372739.
108. Musher, D. M.,, and B. L. Musher. 2004. Contagious acute gastrointestinal infections. N. Engl. J. Med. 351: 24172427.
109. Musher, D. M.,, F. Nuila,, and N. Logan. 2007. The long-term outcome of treatment of Clostridium difficile colitis. Clin. Infect. Dis. 45: 523524.
110. Muto, C. A.,, M. Pokrywka,, K. Shutt,, A. B. Mendelsohn,, K. Nouri,, K. Posey,, T. Roberts,, K. Croyle,, S. Krystofiak,, S. Patel-Brown,, A. W. Pasculle,, D. L. Paterson,, M. Saul,, and L. H. Harrison. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26: 273280.
111. Nair, S.,, D. Yadav,, M. Corpuz,, and C. S. Pitchumoni. 1998. Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation. Am. J. Gastroenterol. 93: 18731876.
112. Nathanson, D. R.,, M. Sheahan,, L. Chao,, and M. K. Wallack. 2001. Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case. Dis. Colon Rectum 44: 18711872.
113. Nelson, R. 2007. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 2007: CD004610.
114. Noren, T.,, T. Akerlund,, E. Back,, L. Sjoberg,, I. Persson,, I. Alriksson,, and L. G. Burman. 2004. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J. Clin. Microbiol. 42: 36353643.
115. Nusrat, A.,, C. von Eichel-Streiber,, J. R. Turner,, P. Verkade,, J. L. Madara,, and C. A. Parkos. 2001. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect. Immun. 69: 13291336.
116. O’Connor, K. A.,, M. Kingston,, M. O’Donovan,, B. Cryan,, C. Twomey,, and D. O’Mahony. 2004. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM 97: 423429.
117. Olson, M. M.,, C. J. Shanholtzer,, J. T. Lee, Jr., and, D. N. Gerding. 1994. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect. Control. Hosp. Epidemiol. 15: 371381.
118. O’Neill, G. L.,, M. H. Beaman,, and T. V. Riley. 1991. Relapse versus reinfection with Clostridium difficile. Epidemiol. Infect. 107: 627635.
119. Parada, J. P.,, I. Soneru,, F. Lambert-Smith,, M. Ginsburg,, G. Giangreco,, P. Priyardashiri,, K. Hur,, S. Miskevics,, and S. Imam. 2007. 45th Annu. Meet. Infect. Dis. Soc. Am., San Diego, CA, abstr. 818.
120. Pavliakova, D.,, J. S. Moncrief,, D. M. Lyerly,, G. Schiffman,, D. A. Bryla,, J. B. Robbins,, and R. Schneerson. 2000. Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect. Immun. 68: 21612166.
121. Pear, S. M.,, T. H. Williamson,, K. M. Bettin,, D. N. Gerding,, and J. N. Galgiani. 1994. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann. Intern. Med. 120: 272277.
122. Pelaez, T.,, L. Alcala,, R. Alonso,, M. Rodriguez-Creixems,, J. M. Garcia-Lechuz,, and E. Bouza. 2002. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46: 16471650.
123. Pepin, J.,, M. E. Alary,, L. Valiquette,, E. Raiche,, J. Ruel,, K. Fulop,, D. Godin,, and C. Bourassa. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40: 15911597.
124. Pepin, J.,, L. Valiquette,, M. E. Alary,, P. Villemure,, A. Pelletier,, K. Forget,, K. Pepin,, and D. Chouinard. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171: 466472.
125. Persky, S. E.,, and L. J. Brandt. 2000. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am. J. Gastroenterol. 95: 32833285.
126. Plummer, S.,, M. A. Weaver,, J. C. Harris,, P. Dee,, and J. Hunter. 2004. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int. Microbiol. 7: 5962.
127. Pochapin, M. 2000. The effect of probiotics on Clostridium difficile diarrhea. Am. J. Gastroenterol. 95: S11S13.
128. Poutanen, S. M.,, and A. E. Simor. 2004. Clostridium difficile-associated diarrhea in adults. CMAJ 171: 5158.
129. Riegler, M.,, R. Sedivy,, C. Pothoulakis,, G. Hamilton,, J. Zacherl,, G. Bischof,, E. Cosentini,, W. Feil,, R. Schiessel,, J. T. LaMont, et al. 1995. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J. Clin. Investig. 95: 20042011.
130. Ripa, S.,, F. Mignini,, M. Prenna,, and E. Falcioni. 1987. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp. Clin. Res. 13: 483488.
131. Rocha, M. F.,, M. E. Maia,, L. R. Bezerra,, D. M. Lyerly,, R. L. Guerrant,, R. A. Ribeiro,, and A. A. Lima. 1997. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1β, tumor necrosis factor alpha, and leukotrienes. Infect. Immun. 65: 27402746.
132. Ross, J. J.,, C. L. Saltzman,, P. Carling,, and D. S. Shapiro. 2003. Pneumococcal septic arthritis: review of 190 cases. Clin. Infect. Dis. 36: 319327.
133. Salcedo, J.,, S. Keates,, C. Pothoulakis,, M. Warny,, I. Castagliuolo,, J. T. LaMont,, and C. P. Kelly. 1997. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41: 366370.
134. Samore, M. H.,, P. C. DeGirolami,, A. Tlucko,, D. A. Lichtenberg,, Z. A. Melvin,, and A. W. Karchmer. 1994. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin. Infect. Dis. 18: 181187.
135. Schwan, A.,, S. Sjolin,, U. Trottestam,, and B. Aronsson. 1984. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand. J. Infect. Dis. 16: 211215.
136. Seal, D.,, S. P. Borriello,, F. Barclay,, A. Welch,, M. Piper,, and M. Bonnycastle. 1987. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur. J. Clin. Microbiol. 6: 5153.
137. Settle, C. D.,, M. H. Wilcox,, W. N. Fawley,, O. J. Corrado,, and P. M. Hawkey. 1998. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment. Pharmacol. Ther. 12: 12171223.
138. Shaw, J. B.,, and N. Wynn-Williams. 1954. Infectivity of pulmonary tuberculosis in relation to sputum status. Am. Rev. Tuberc. 69: 723732.
139. Shim, J. K.,, S. Johnson,, M. H. Samore,, D. Z. Bliss,, and D. N. Gerding. 1998. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351: 633636.
140. Silva, J.,, Jr., D. H. Batts,, R. Fekety,, J. F. Plouffe,, G. D. Rifkin,, and I. Baird. 1981. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am. J. Med. 71: 815822.
141. Surawicz, C. M.,, L. V. McFarland,, G. Elmer,, and J. Chinn. 1989. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am. J. Gastroenterol. 84: 12851287.
142. Tang-Feldman, Y.,, S. Mayo,, J. Silva, Jr.,, and S. H. Cohen. 2003. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 41: 34133414.
143. Taylor, N. S.,, and J. G. Bartlett. 1980. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J. Infect. Dis. 141: 9297.
144. Teasley, D. G.,, D. N. Gerding,, M. M. Olson,, L. R. Peterson,, R. L. Gebhard,, M. J. Schwartz,, and J. T. Lee, Jr. 1983. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2: 10431046.
145. Tedesco, F. J.,, R. W. Barton,, and D. H. Alpers. 1974. Clindamycin-associated colitis. A prospective study. Ann. Intern. Med. 81: 429433.
146. Torres, J. F.,, D. M. Lyerly,, J. E. Hill,, and T. P. Monath. 1995. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63: 46194627.
147. Viscidi, R.,, S. Willey,, and J. G. Bartlett. 1981. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 81: 59.
148. Walker, K. J.,, S. S. Gilliland,, K. Vance-Bryan,, J. A. Moody,, A. J. Larsson,, J. C. Rotschafer,, and D. R. Guay. 1993. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J. Am. Geriatr. Soc. 41: 940946.
149. Wallace, J. F.,, R. H. Smith,, and R. G. Petersdorf. 1965. Oral administration of vancomycin in the treatment of staphylococcal enterocolitis. N. Engl. J. Med. 272: 10141015.
150. Wanahita, A.,, B. Davis,, R. J. Hamill,, E. A. Goldsmith,, J. R. Rodgers,, R. G. Cook,, J. G. Lamphear,, and D. M. Musher. 2006. Clostridium difficile lacks detectable superantigen activity. FEMS Immunol. Med. Microbiol. 47: 275277.
151. Wanahita, A.,, E. Goldsmith,, and D. Musher. 2002. Leukocytosis in a tertiary care hospital with particular attention to the role of infection caused by Clostridium difficile. Clin. Infect. Dis. 34: 15851592.
152. Ward, J. I.,, and K. Zangwill. 1999. Haemophilus influenzae vaccines, p. 183–221. In S. A. Plotkin and, W. A. Orenstein (ed.), Vaccines, 3rd ed. W.B. Saunders, Philadelphia, PA.
153. Warny, M.,, J. Pepin,, A. Fang,, G. Killgore,, A. Thompson,, J. Brazier,, E. Frost,, and L. C. McDonald. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 10791084.
154. Warny, M.,, J. P. Vaerman,, V. Avesani,, and M. Delmee. 1994. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62: 384389.
155. Warren, C. A.,, L. Archibald-Pannone,, G. A. C. Brito,, P. B. Ernst,, J. M. Linden,, and R. L. Guerrant. 2007. 45th Annu. Meet. Infect. Dis. Soc. Amer., San Diego, CA, abstr. 430.
156. Wenisch, C.,, B. Parschalk,, M. Hasenhundl,, A. M. Hirschl,, and W. Graninger. 1996. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22: 813818.
157. White, C. A., Jr. 2004. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev. Anti Infect. Ther. 2: 4349.
158. Wilcox, M. H. 2004. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 53: 882884.
159. Wilcox, M. H.,, J. G. Cunniffe,, C. Trundle,, and C. Redpath. 1996. Financial burden of hospital-acquired Clostridium difficile infection. J. Hosp. Infect. 34: 2330.
160. Wilcox, M. H.,, W. N. Fawley,, N. Wigglesworth,, P. Parnell,, P. Verity,, and J. Freeman. 2003. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J. Hosp. Infect. 54: 109114.
161. Wilcox, M. H.,, J. Freeman,, W. Fawley,, S. MacKinlay,, A. Brown,, K. Donaldson,, and O. Corrado. 2004. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 54: 168172.
162. Wong, S. S.,, P. C. Woo,, W. K. Luk,, and K. Y. Yuen. 1999. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn. Microbiol. Infect. Dis. 34: 16.
163. Wullt, M.,, M. L. Hagslatt,, and I. Odenholt. 2003. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 35: 365367.
164. Young, G. P.,, P. B. Ward,, N. Bayley,, D. Gordon,, G. Higgins,, J. A. Trapani,, M. I. McDonald,, J. Labrooy,, and R. Hecker. 1985. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89: 10381045.
165. Zafar, A. B.,, L. A. Gaydos,, W. B. Furlong,, M. H. Nguyen,, and P. A. Mennonna. 1998. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am. J. Infect. Control 26: 588593.
166. Zar, F. A. 2007. Author reply. Clin. Infect. Dis. 45: 16491651.
167. Zar, F. A.,, S. R. Bakkanagari,, K. M. Moorthi,, and M. B. Davis. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45: 302307.
168. Zukowski, W. E.,, K. Nagaro,, A. Cheknis,, S. P. Sambol,, S. Johnson,, and D. N. Gerding. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr. K-602.


Generic image for table
Table 1.

Factors contributing to the recent increase in disease

Citation: Musher D, Aslam S. 2008. Disease, p 313-335. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch16
Generic image for table
Table 2.

Treatments for colitis

Citation: Musher D, Aslam S. 2008. Disease, p 313-335. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch16

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error